Overview

Major Brands

• Mounjaro (for diabetes) and Zepbound (for obesity)

How it Works

• Dual agonist of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

• Adds the GIP pathway on top of GLP-1 activity, further enhancing insulin response and fat-metabolism effects.

Effects

• Tends to produce greater weight loss and metabolic improvements than semaglutide in head-to-head studies.

• Average weight loss (Zepbound trials): ~21% of body weight.